The research team, led by Mei-Ling Li and Kuo-Chiang Hsu of China Medical University in Taiwan, chose pork for good reason: pork accounts for 32.8 percent of total meat intake in Taiwan, and charcoal-grilled pork is a staple of both household kitchens and street-food stalls. The investigators freeze-dried eight fresh fruits—guava, strawberry, lemon, kumquat, papaya, tankan orange, passion fruit, and banana—purchased from a local market in Taichung, milling the dried material into powders that could be standardized and dosed precisely. Four powders, guava, strawberry, lemon, and kumquat, were selected for meat experiments after screening showed they consistently outperformed the others in antioxidant capacity relative to their sugar content. The team then grilled pork loin and pork belly over a charcoal bed held at 500 ± 20 °C, monitored by infrared thermometry, until the geometric center of the meat reached 72 °C, the endpoint verified by thermocouple.

A key innovation of the study was treating the application method itself as a controllable processing variable rather than a fixed detail. The researchers compared three approaches: marinating, in which meat is immersed in a fruit powder solution for two hours at 4 °C; spraying, in which a calibrated atomizer delivers a mass-matched amount directly onto the surface; and mixing, in which ground patties are blended with an equivalent dry-matter loading of powder plus salt. Using a two-way analysis of variance to decompose the sources of variation in AGE inhibition, they found that in lean pork loin the application method accounted for a striking 62 percent of the total variance, compared with only 13 percent for fruit type and 17 percent for the interaction between the two. In other words, the way the protective formulation reached the meat mattered far more than the identity of the fruit itself.

The picture changed dramatically in the fattier pork belly, where the method contribution fell to 35 percent and the interaction term rose to 30 percent. Here the team uncovered a paradox that illustrates why sugar chemistry cannot be ignored: marinating pork belly with strawberry powder produced a negative inhibition rate of −142.5 percent, meaning AGE formation was dramatically promoted rather than suppressed. The likely culprit is the prolonged immersion, which allowed the strawberry powder’s high fructose and glucose loads—18.8 and 16.2 grams per 100 grams of dry powder, respectively—to penetrate the fat-rich intramuscular space and overwhelm the protective polyphenols delivered alongside them. Because fructose is eight to ten times more reactive than glucose in Maillard chemistry, sugar-rich fruit ingredients can actively backfire if they are given time and access to diffuse into the meat. Spraying, by contrast, kept inhibition above 60 percent for both kumquat (70.5 percent) and strawberry (60.9 percent) in belly, precisely because it confined the formulation to the surface without extended exposure.

These findings led the researchers to propose a new formulation-screening criterion: the antioxidant-to-reducing-sugar ratio, calculated as total phenolic or flavonoid content divided by the combined glucose and fructose burden. Guava, despite posting the highest ferric reducing antioxidant power (104.88 mg FeSO4 equivalents per gram) and the highest total phenolic content, carried the heaviest sugar load at 55.2 grams per 100 grams, yielding a phenolic-to-sugar ratio of just 0.35. Kumquat, with the highest flavonoid content (29.87 mg quercetin equivalents per gram) and comparatively low glucose, achieved the most favorable ratios. Correlation analysis reinforced the point: the phenolic-to-sugar ratios positively predicted AGE inhibition in belly-marinating conditions (r = 0.61 to 0.73), while FRAP alone actually showed a significant negative correlation with inhibition in loin-spraying conditions (r = −0.69). Conventional antioxidant metrics, the authors conclude, can be actively misleading when applied to fruit powder treatments in meat.

To translate the laboratory findings into something a home cook or food manufacturer could actually use, the team formulated two sprayable barbecue sauces: one containing soy sauce and one soy sauce-free, each fortified with the selected fruit powders, adjusted to pH 4.2–4.4, and hot-filled into 150-milliliter fine-mist spray bottles. The soy sauce choice proved consequential. The soy sauce-containing blank itself elevated total AGEs in pork belly by 58.2 percent over the untreated control, rising from 2.02 to 3.19 micrograms per gram, because the fermentation-derived free amino acids and reducing sugars in soy sauce serve as extra Maillard substrates during grilling. The soy sauce-free base, by contrast, actually reduced total AGEs by 27.4 percent in loin and 14.2 percent in belly on its own, providing a cleaner background against which the fruit polyphenols could work.

The final performance numbers were remarkable. In the soy sauce-free system, strawberry powder achieved the highest inhibition in pork loin, cutting total AGEs from 2.59 to 0.44 micrograms per gram—an 83.1 percent reduction versus the untreated control—with CML falling 98.2 percent, from 1.64 to 0.03 micrograms per gram. Kumquat powder delivered the best results in belly, reducing total AGEs from 2.02 to 0.28 micrograms per gram, an 86.2 percent reduction, with CML down 97.7 percent. The preferential suppression of CML over CEL suggests the sprays more efficiently blocked the oxidative glycation routes that produce CML than the methylglyoxal-associated pathways that feed CEL. Guava, despite its stellar antioxidant credentials, managed only 6.1 percent inhibition in the soy sauce-containing belly formulation, once again demonstrating that a high reducing-sugar load can negate antioxidant benefits even in a spray format.

Crucially, the optimized formulations passed the practical tests that determine whether a laboratory success can become a kitchen reality. Both strawberry and kumquat sprays significantly reduced lipid oxidation, cutting TBARS values by 53.0 and 32.3 percent respectively in loin, with all treated samples far below the 2.0 mg malondialdehyde per kilogram threshold associated with rancidity. A consumer panel of fifty tasters rated both sauces well above the neutral point on a nine-point hedonic scale, with strawberry earning an overall liking score of 6.33 and kumquat 6.14, and lemon was dropped from further development after panelists flagged pronounced bitterness from citrus limonoids. During accelerated storage at 45 °C for 90 days, both sauces retained more than 80 percent of their initial flavonoid content and kept AGE inhibition rates between roughly 51 and 84 percent depending on matrix and powder, while triangle tests found the flavor indistinguishable from the day-zero reference throughout the entire storage period.

To explain why the sprays work, the researchers combined untargeted metabolomics with computational and biochemical probes. Twenty-eight polyphenols identified in the kumquat and strawberry powders were docked against four glycation-susceptible hotspots on porcine myosin, using an AlphaFold-predicted protein structure; 27 of the 28 bound more strongly than glucose, and all 28 outcompeted the reactive carbonyl intermediates methylglyoxal and glyoxal, with top performers including hesperidin, neohesperidin, and procyanidin B2. Methylglyoxal-trapping assays then revealed a clear structure–activity relationship: dihydromyricetin, with three free hydroxyl groups on its B-ring, trapped 85.2 percent of methylglyoxal, while fully methoxylated nobiletin trapped a negligible 2.1 percent despite moderate docking affinity. The authors propose a three-pathway model in which polyphenols competitively occupy glycation sites on myosin, directly trap reactive dicarbonyl intermediates, and suppress lipid oxidation that would otherwise generate secondary reactive carbonyls. While the docking and trapping data do not constitute direct proof inside the grilled-meat matrix, they offer a coherent molecular framework for a deceptively simple message: when it comes to healthier grilling, a fine mist of the right fruit powder, applied at the right moment, may matter as much as what is in the bottle.

Subject of Research: Reducing advanced glycation end-product formation in charcoal-grilled pork using spray-applied fruit powder formulations

Article Title: Fruit powder spray formulations reduce advanced glycation end-product formation in charcoal-grilled pork: effects of application method and polyphenol–sugar balance

Article References: Li, M.-L., Huang, S.-M., Wu, P.-Y., Huang, C.-W., Hung, W.-L., & Hsu, K.-C. (2026). Fruit powder spray formulations reduce advanced glycation end-product formation in charcoal-grilled pork: effects of application method and polyphenol–sugar balance. Current Research in Food Science, 13, Article 101592. https://doi.org/10.1016/j.crfs.2026.101592

Image Credits: AI Generated

DOI: 10.1016/j.crfs.2026.101592

Keywords: advanced glycation end-products, charcoal grilling, fruit powder, polyphenols, Maillard reaction, pork, food chemistry, spray application, CML, CEL, methylglyoxal, barbecue sauce

Methylglyoxal is a small, electrophilic ketoaldehyde produced as a byproduct of carbohydrate metabolism. In many organisms it arises when the flow of sugar phosphates through central metabolism becomes imbalanced, particularly when dihydroxyacetone phosphate accumulates. The enzyme methylglyoxal synthase, encoded by the mgsA gene, channels this intermediate into methylglyoxal rather than allowing it to continue down the glycolytic route. Once formed, methylglyoxal attacks nucleophilic side chains on amino acids, most notably lysine, arginine, and cysteine residues, forming covalent adducts known as advanced glycation end products. These modifications can distort protein structure, interfere with enzyme active sites, and disrupt protein-protein interactions. Because of this destructive chemistry, the accumulation of methylglyoxal has been described as carbonyl stress, a condition generally assumed to be harmful or outright lethal to microbial cells.

The research team set out to determine whether this pathway even operates in spirochetes, a group of spiral-shaped bacteria with distinctive genetics and metabolism. B. burgdorferi has an unusually reduced genome and depends almost entirely on its tick and mammalian hosts for nutrients, so the question of how it manages carbohydrate and phosphate balance is biologically important. The investigators identified several environmental signals that trigger carbonyl stress in the Lyme disease spirochete, including glycerol and peptides. Glycerol is particularly interesting because B. burgdorferi can use it as a carbon source during its tick phase, when blood is unavailable and the bacterium must survive on alternative substrates. Peptides, meanwhile, reflect the amino acid-rich environment the spirochete encounters in mammalian tissues and blood. The finding that both classes of nutrients feed into the carbonyl stress pathway suggests that methylglyoxal production is tied to the specific metabolic states the bacterium passes through during its enzootic cycle between tick and host.

Central to the study was the demonstration that methylglyoxal production and the resulting glycation of proteins depend on the product of the mgsA gene, designated bb0364 in the B. burgdorferi genome. When this gene’s function was removed, the spirochete no longer produced detectable methylglyoxal, and the characteristic protein adducts of advanced glycation disappeared. This genetic dependency establishes that the pathway is not an incidental chemical side reaction but a controlled enzymatic process. The researchers could therefore treat mgsA as a molecular switch, turning carbonyl stress on or off and observing the consequences for the bacterium’s physiology and its ability to infect animals.

One of the most consequential discoveries was phylogenetic. The carbonyl stress pathway proved to be active in Lyme disease spirochetes but absent in function from relapsing fever Borrelia species and from B. mayonii, another human pathogen in the Lyme disease group. Relapsing fever spirochetes are famous for achieving enormous densities in the bloodstream, cycling through antigenic variation to evade antibodies and producing recurrent febrile episodes. The fact that these blood-dwelling relatives lack an active methylglyoxal pathway, while the tissue-adapted Lyme disease spirochete retains one, hints at an evolutionary trade-off. The authors suggest that carbonyl stress may be selected against in spirochetes that reach high numbers in the blood, where the metabolic consequences of glycation could become intolerable at large population sizes.

To test whether methylglyoxal production matters during actual infection, the team turned to the tick-mouse model of Lyme disease, the standard experimental system for studying B. burgdorferi in its natural transmission context. Ticks infected with spirochetes were allowed to feed on mice, and the course of infection was followed through the mammalian host. The results provided evidence that the production of methylglyoxal and the glycation of proteins are not necessarily lethal to the spirochete, at least in this organism, contradicting the long-standing assumption that carbonyl stress is uniformly toxic. Bacteria carrying an intact pathway persisted through the infection cycle, indicating that B. burgdorferi can tolerate a level of self-inflicted protein damage that would cripple many other microbes. This tolerance raises the possibility that the pathway confers some benefit that offsets its biochemical costs.

The clearest hint of that benefit came from an elegant cross-species experiment. The researchers introduced the B. burgdorferi mgsA gene and its associated carbonyl stress pathway into B. hermsii, a relapsing fever spirochete that naturally lacks the system. When the engineered bacteria were used to infect mice, the peak level of spirochetemia during the relapse phase of infection dropped significantly compared with infections caused by unmodified B. hermsii. In other words, forcing a blood-dwelling spirochete to run the Lyme disease carbonyl stress pathway curtailed its ability to flood the bloodstream. This result supports the idea that methylglyoxal production imposes a cost on explosive growth in blood, and it explains why relapsing fever species, which depend on high-density blood infections for transmission, would have lost or never maintained this pathway.

Taken together, these findings define a previously unrecognized post-translational modification system in B. burgdorferi. Rather than relying solely on the phosphorylation, acetylation, and proteolytic processing that bacteria typically use to tune protein function, the Lyme disease spirochete appears to exploit direct chemical glycation by methylglyoxal as a regulatory layer. Because the pathway is triggered by glycerol and peptides, nutrients encountered at particular stages of the tick-mouse cycle, methylglyoxal-mediated modification could help the bacterium reprogram its proteome as it transitions between metabolically distinct environments. Proteins damaged by glycation might be preferentially degraded, redirected, or inactivated, allowing the spirochete to adjust its physiology in ways that standard transcriptional regulation alone cannot achieve.

The study also reframes how scientists think about carbonyl stress in microbial pathogenesis. For decades, methylglyoxal has been studied mainly as a threat that bacteria must detoxify through glyoxalase systems and related enzymes. The new work shows that at least one pathogen has integrated this reactive metabolite into its normal biology, tolerating the damage it causes and possibly using it to govern its lifestyle. The contrast between Lyme disease and relapsing fever spirochetes offers a natural experiment in evolutionary strategy: one pathogen persists at low densities in collagen-rich tissues for months or years, while the other races through the blood in massive waves. The presence of an active carbonyl stress pathway in the former and its apparent incompatibility with the latter suggests that methylglyoxal biology is entwined with the fundamental ecological strategies of these bacteria.

Future work will need to identify which B. burgdorferi proteins are glycated in vivo, how those modifications alter protein function, and whether the pathway influences the bacterium’s ability to establish persistence in joints, heart, and nervous system tissue. The findings also raise questions about whether carbonyl stress contributes to the chronic inflammatory environment characteristic of Lyme disease, since advanced glycation end products are known to interact with host immune receptors in other contexts. For now, the study stands as a vivid example of how a molecule once dismissed as metabolic waste can turn out to be a purposeful instrument of pathogen regulation, and it underscores how much remains to be learned from comparing closely related spirochetes that have evolved to occupy radically different niches within their hosts.

Subject of Research: Methylglyoxal-mediated carbonyl stress and protein glycation regulation in Lyme disease and relapsing fever spirochetes

Article Title: Metabolic regulation of the carbonyl stress pathway and methylglyoxal in Lyme disease and relapsing fever spirochetes

Article References: Drecktrah, D., Hall, L. S., Cheff, B., Richards, C., Raffel, S. J., Wulf, M., Bailey, I. T., Gherardini, F., & Samuels, D. S. (2026). Metabolic regulation of the carbonyl stress pathway and methylglyoxal in Lyme disease and relapsing fever spirochetes. PLOS Pathogens, 22(9), e1014657. https://doi.org/10.1371/journal.ppat.1014657

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014657

Keywords: Lyme disease, Borrelia burgdorferi, methylglyoxal, carbonyl stress, advanced glycation end products, mgsA, spirochetes, relapsing fever, Borrelia hermsii, protein glycation, tick-mouse model, metabolic regulation

The study, published in Applied Microbiology and Biotechnology, focused on two of the most clinically relevant and drug-resistant organisms found in chronic wounds: Staphylococcus aureus and Pseudomonas aeruginosa. These species are frequent co-inhabitants of non-healing wounds, where they cooperate within mixed biofilms that are far more tolerant to treatment than free-floating planktonic bacteria. Rather than reaching for another antibiotic, the Italian team, led by Silvia Di Lodovico and Mara Di Giulio, tested a combination protected by Italian patent N. 102022000024408, a composition designed for the treatment of skin lesion infections. The approach is deliberately multi-target, aiming to stress pathogens through several mechanisms at once rather than relying on a single lethal hit that bacteria can easily evolve around.

Methylglyoxal, the small molecule at the heart of the combination, is a reactive dicarbonyl compound best known as the major antibacterial principle of manuka honey. It works by glycating bacterial proteins and damaging cells through chemical modification, a mode of action that is difficult for microbes to neutralize. In the new experiments, the researchers first determined the minimum inhibitory concentration of methylglyoxal against clinical isolates of antimicrobial-resistant S. aureus and P. aeruginosa. The MIC values ranged from 32 to 128 milligrams per liter, confirming that the strains were susceptible at concentrations that are considered achievable and non-toxic in wound care contexts.

Graphene oxide, the second component, is a two-dimensional carbon nanomaterial decorated with oxygen-containing functional groups. Its antibacterial reputation rests on physical and chemical actions: sharp nanosheet edges can contact and stress bacterial membranes, while its surface chemistry can promote oxidative stress and disrupt cellular integrity. Crucially, graphene oxide can also serve as a delivery platform, adsorbing small molecules onto its expansive surface and presenting them to microbial cells at high local concentrations. The researchers hypothesized that combining the nanomaterial with methylglyoxal would produce more than the sum of its parts, and they set out to quantify exactly how the two agents interact.

To measure the interaction, the team used the checkerboard test, a standard microbiological method that exposes bacteria to a grid of two-dimensional dilutions of both agents and calculates whether the outcome is synergistic, additive, or antagonistic. The results revealed a striking species-specific pattern. Against S. aureus, graphene oxide and methylglyoxal acted synergistically, meaning the combination was significantly more effective than either agent alone at the same doses. Against P. aeruginosa, the interaction was additive: the two agents still worked better together than separately, but their effects simply stacked rather than multiplying. This distinction matters, because it shows the combination is broadly useful while hinting that the two pathogens respond differently to the treatment’s mechanisms.

The optimal formulation identified in the study combined 6.25 milligrams per liter of graphene oxide with 64 milligrams per liter of methylglyoxal. When the researchers probed what this combination was doing to the bacteria, one finding stood out: the treatment increased bacterial membrane fluidity. Membrane fluidity is a sensitive indicator of cellular stress, and a shift in the physical state of the lipid bilayer can impair transport, energy generation, and envelope integrity. This observation suggests that the GO plus MGO combination destabilizes the bacterial cell envelope, potentially making cells more vulnerable to the glycation damage inflicted by methylglyoxal and to the physical stress imposed by the nanosheets.

The most demanding test came in the Lubbock Chronic Wound Biofilm model, a recognized in vitro system that recreates the polymicrobial biofilms characteristic of real chronic wounds. The researchers applied the GO plus MGO combination both to biofilms that were still forming, described as informing biofilms, and to mature, established biofilms. In both cases, the treatment reduced viable bacterial counts by 60 to 80 percent, measured as colony-forming units per milligram of biofilm. Dismantling a mature polymicrobial biofilm is notoriously difficult, and a reduction of this magnitude using non-toxic, non-antibiotic concentrations is a notable result for a field where biofilm tolerance routinely defeats standard therapies.

The combination also struck a blow against Pseudomonas aeruginosa’s motility, specifically its twitching motility, the surface-crawling movement powered by type IV pili that helps the bacterium colonize tissue and spread across wound surfaces. Inhibiting this motility could slow the expansion of infection within a wound bed and reduce the pathogen’s ability to reach and colonize new territory. Taken together with the membrane effects and the biofilm reductions, the picture that emerges is one of multi-target action: the combination attacks the envelope, the biofilm structure, and the behavioral machinery of the pathogens simultaneously, leaving fewer escape routes for resistance to develop.

An important practical aspect of the study is that the effective concentrations fall within ranges recognized as non-toxic, which is essential for any topical wound treatment. The authors describe the GO plus MGO combination as a valid and innovative non-antibiotic solution for wound management, one that acts on polymicrobial chronic wound biofilms and on P. aeruginosa motility without contributing to the antibiotic resistance crisis. Because neither component is a conventional antibiotic, the selective pressure that drives classic resistance mechanisms is reduced, an increasingly urgent consideration as antimicrobial resistance continues to climb worldwide.

The work, which was published open access on 24 September 2026 and carried out at the Department of Pharmacy and the Department of Medical, Oral and Biotechnological Sciences in Chieti, adds to a growing body of research exploring nanomaterial-honey compound partnerships for infection control. The authors note that the article was shared early to provide faster access to peer-reviewed, accepted research, with a final version of record to follow. If the laboratory findings translate into clinical settings, the graphene oxide and methylglyoxal pairing could offer clinicians a much-needed tool for wounds that have exhausted every antibiotic option, turning a two-pronged chemical and physical assault into a practical strategy for healing that has, until now, remained out of reach.

Subject of Research: A graphene oxide and methylglyoxal combination as a non-antibiotic treatment for polymicrobial chronic wound biofilms

Article Title: Graphene Oxide and Methylglyoxal: a combined strategy against chronic wound pathogens

Article References: Di Lodovico, S., Fontana, A., Di Fermo, P., Diban, F., Di Campli, E., Pilato, S., D’Ercole, S., Cellini, L., & Di Giulio, M. (2026). Graphene Oxide and Methylglyoxal: a combined strategy against chronic wound pathogens. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14050-2

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14050-2

Keywords: graphene oxide, methylglyoxal, chronic wounds, biofilms, Staphylococcus aureus, Pseudomonas aeruginosa, antimicrobial resistance, wound healing, nanomaterials, Lubbock Chronic Wound Biofilm model, membrane fluidity, non-antibiotic therapy

That suspicion has been fueled by a striking clinical observation. Reduced GLO1 expression has been reported both in experimental models of metabolic dysfunction-associated fatty liver disease, or MAFLD, and in liver biopsies from patients with the condition. MAFLD, driven by excessive fat storage in the liver, is estimated to affect roughly 24 percent of the United States population and is present in more than 70 percent of patients with type 2 diabetes, making it one of the most common and consequential comorbidities of the modern obesity pandemic. Sustained consumption of high-carbohydrate diets, particularly those rich in fructose, is a major driving factor in the pathogenesis of both obesity and MAFLD, and fructose-containing foods are capable of inducing insulin resistance in humans and metabolic syndrome in mice. Yet despite the clear association between diminished GLO1 and fatty liver disease, a fundamental question remained unanswered: is the loss of GLO1 a cause of the disease, or merely a compensatory response to it?

A new study published in Physiological Reports by a team at the University of Arizona set out to resolve this question directly. Rather than merely observing correlations, the researchers generated whole-body Glo1 knockout mice using CRISPR-SpCas9 genome editing in the C57Bl/6NN strain, targeting exon 3 of the Glo1 gene with guide RNAs to produce frameshift deletions through non-homologous end joining. They then challenged these mice, alongside wild-type controls, with sixteen weeks of a high-fat, high-sucrose diet containing 36 percent fat and 30 percent sucrose, a regimen well documented to induce fatty liver disease and impair glucose tolerance. The team’s initial hypothesis was straightforward: if reduced GLO1 expression contributes to MAFLD, then deleting the gene should exacerbate metabolic dysfunction by increasing MGO-mediated stress. What they found instead was a surprise that reshapes how the field should think about the glyoxalase system.

Contrary to expectations, the knockout mice were substantially protected from hepatic fat accumulation. When wild-type mice consumed the obesogenic diet, they developed substantial hepatic steatosis, with triglycerides building up in the liver as expected. In the Glo1-deficient mice fed the same diet, this triglyceride accumulation was significantly blunted. The protection was specific to the liver: adipose tissue biology was largely unaffected, with no significant differences in adipocyte size, epididymal white adipose tissue mass, or markers of fat tissue injury between genotypes under the high-fat, high-sucrose conditions. Serum triglycerides and beta-hydroxybutyrate, a readout of fatty acid oxidation, varied only with diet and not with genotype, suggesting that the hepatic phenotype was not secondary to altered fat export or whole-body fat burning. The findings point toward a previously unrecognized role for GLO1 in directly regulating hepatic lipid metabolism, positioning the enzyme as an unexpected participant in the biology of fatty liver rather than a passive bystander.

But the metabolic ledger did not balance cleanly. While the knockout mice enjoyed relative protection from fatty liver, their systemic glucose handling deteriorated in a diet-dependent manner. Fasting blood glucose was significantly elevated in high-fat, high-sucrose-fed knockout mice compared with their wild-type counterparts. Oral glucose tolerance testing revealed a significant reduction in the ability of knockout mice to clear systemic glucose when compared with chow-fed controls, and although the difference between the two genotypes on the obesogenic diet did not reach statistical significance in the raw tolerance curves, a deeper analysis told a more troubling story. The constant of glucose decay, calculated from insulin tolerance testing as the rate of glucose disappearance, revealed a significant reduction in insulin responsiveness specifically in the high-fat, high-sucrose-fed knockout mice. Notably, serum insulin levels and hepatic insulin signaling, assessed through phosphorylation of the insulin receptor and AKT, showed no significant differences, indicating that the glucose defect operates independently of measurable changes in insulin activity.

To understand the biochemistry underlying these divergent phenotypes, the researchers turned to sensitive mass spectrometry-based quantification of MGO and its downstream molecular footprints. Free hepatic MGO was not significantly elevated in any treatment group, and the product of GLO1 activity, lactoylglutathione, was significantly reduced in the knockout mice, consistent with the loss of enzyme function. A complicating factor emerged, however: the high-fat, high-sucrose diet produced a marked reduction in hepatic glutathione regardless of genotype, and because glutathione is required for GLO1 activity, the reduction in lactoylglutathione may partly reflect this glutathione depletion. When the team examined MGO-derived post-translational modifications on proteins, the results were equally nuanced. Levels of MGO-hydroimidazolone 1, a signature MGO-derived arginine modification, were not significantly affected by diet or genotype, while carboxyethylarginine was elevated in chow-fed knockout mice. These data contradict previous reports indicating dramatic elevations in MGO-derived modifications under diet-induced metabolic stress, and they suggest that steady-state MGO biology in vivo is more buffered than cell culture experiments would predict.

The study also delivered a decisive verdict on a long-standing controversy in diabetes research. Earlier work using short hairpin RNA to knock down Glo1 reported that reduced GLO1 activity could spontaneously generate pathologies resembling diabetic nephropathy in non-diabetic mice, fueling the idea that GLO1 loss is a primary driver of diabetic kidney disease. The Arizona team therefore reasoned that sixteen weeks of high-fat, high-sucrose feeding would exacerbate kidney injury in their knockout animals. Instead, they found no evidence of renal pathology attributable to GLO1 loss. Kidney glycogen accumulated with the obesogenic diet but was unaffected by genotype, serum urea and creatinine were unchanged across all cohorts, and renal levels of MGO-hydroimidazolone 1, carboxyethylarginine, and 3-nitrotyrosine, a modification associated with oxidative stress, showed no significant differences. These findings independently confirm earlier reports from a separate group that complete genetic deletion of Glo1 fails to reproduce the diabetic kidney phenotype seen with knockdown approaches, and they collectively indicate that loss of GLO1 alone is insufficient to drive diabetic nephropathy.

Why might deleting a detoxification enzyme protect the liver while harming glucose control? The authors offer several mechanistic possibilities grounded in their own prior work. In cultured fibroblasts, they previously showed that loss of GLO1 reduces glucose uptake and glycolytic flux, and that Glo1-deficient cells fail to differentiate into mature adipocytes. If a similar reduction in glycolytic flux occurs in the livers of knockout mice in vivo, it would limit the substrate available for MGO generation, potentially explaining why free MGO and MGO-derived modifications remain largely unchanged despite the absence of the primary detoxification enzyme. Reduced glycolytic flux could also directly limit de novo lipogenesis, the pathway by which the liver converts excess carbohydrate into fat, providing a plausible mechanism for the blunted hepatic triglyceride accumulation. Meanwhile, the concept that MGO is not simply a toxin but a concentration-dependent metabolic signal is gaining traction: modest elevations of MGO have been reported to be protective in cardiac ischemia-reperfusion injury and even stimulatory for tumor growth, while only cytotoxic concentrations far exceeding those measured in vivo cause cell death.

The authors are careful to note the limitations of their work. The dietary intervention was terminated at sixteen weeks, a timepoint at which significant hepatic steatosis is evident but more advanced features of MAFLD, such as frank inflammation and fibrosis, have not yet developed. Whether GLO1 influences disease progression at later stages, including the transition to metabolic dysfunction-associated steatohepatitis, remains unknown and is a focus of ongoing investigation. The study also focused on male mice, leaving potential sex differences unexplored, and it did not evaluate alternative MGO detoxification pathways, such as the aldehyde dehydrogenases and aldose reductase, which are thought to play secondary roles but could become important under chronic metabolic stress. Samples for insulin signaling analysis were collected from fed rather than fasted mice, so the effect of GLO1 on glucose-stimulated insulin secretion could not be assessed.

Even with these caveats, the study carries a clear and provocative message: hepatic lipid accumulation and systemic glycemic control are mechanistically distinct in the absence of GLO1, and the glyoxalase system sits at an unexpected crossroads between the two. For a field that has largely treated MGO as a toxic metabolic accident and GLO1 as a straightforward protective enzyme, the demonstration that complete GLO1 loss limits fatty liver while impairing glucose handling in obese male mice demands a more sophisticated view. Future investigations aimed at deciphering the tissue-specific roles of GLO1 in whole-body glucose tolerance and lipid metabolism may reveal whether the glyoxalase cycle, long relegated to the footnotes of biochemistry textbooks, holds therapeutic potential for one of the most common liver diseases of our time.

Subject of Research: The role of glyoxalase 1 in obesity-associated fatty liver disease, glucose homeostasis, and kidney health in mice.

Article Title: Glyoxalase 1 loss reduces fatty liver but impairs glucose handling in male mice

Article References: Hoffman, E. A., Phoebe, A. M., Trujillo, M. N., Zhang, W. C., Jennings, E. Q., Farrera, D. O., Orlicky, D. J., Rutt, L. N., McCullough, R. L., Huacachino, A. A., Marcinkiewicz, M. M., Snyder, N. W., Bruner, K. R., Payan, K. B., Martinez, D. J. F., Stern, J. H., & Galligan, J. J. (2026). Glyoxalase 1 loss reduces fatty liver but impairs glucose handling in male mice. Physiological Reports, 14(17), Article e71106. https://doi.org/10.14814/phy2.71106

Image Credits: AI Generated

DOI: 10.14814/phy2.71106

Keywords: glyoxalase 1, methylglyoxal, fatty liver disease, MAFLD, glucose tolerance, hepatic triglycerides, glyoxalase cycle, high-fat high-sucrose diet, diabetic nephropathy, glycolysis, post-translational modifications, knockout mice